Obesity update and strong financials boost Amgen share price

3 May 2024
amgen_big

Amgen (Nasdaq: AMGN) has reported better-than-expected first quarter 2024 results, with simultaneous news from its obesity pipeline lifting the firm’s stock price by almost 15%.

For the first quarter, total revenues increased 22% to $7.4 billion, with product sales growing 22%, driven by 25% volume growth.

The firm reported a loss per share of $0.21 for the first quarter, down from $5.28 for the first quarter of 2023, driven by a mark-to-market loss on its BeiGene (Nasdaq: BGNE) equity investment and higher operating expenses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology